Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07648381

Corpus Luteum Function and Cardiovascular Adaptation in a Natural MOCK Cycle.

In infertility treatment, embryos are created in vitro after eggs have been fertilised by sperm using in vitro fertilisation or intracytoplasmic sperm injection techniques. These embryos, resulting from hormonal ovarian stimulation, can be transferred shortly after egg retrieval (fresh transfer) or frozen for later use. Both natural menstrual cycles and artificial cycles (using hormones to mimic a normal cycle) can prepare the uterus for embryo transfer. Patients with regular menstrual cycles often prefer the non-medicated approach. However, these cycles offer less flexibility in timing because they rely on ovulation. As the number of FET cycles increases worldwide, scientists are exploring the possibility of inducing ovulation in smaller follicles to increase the flexibility of natural cycles. However, the safety for future pregnancies is unknown. This study aims to better understand the function of the corpus luteum, the follicle remnant in the ovary after ovulation, by measuring several factors that change throughout the cycle due to substances produced by the corpus luteum. The results of the study will have a direct impact on clinical practice by increasing the flexibility of frozen transfer cycles.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age below 40 years
  • Regular menstrual cycles (between 25-35 days)
  • Normal BMI between 18.5 and 35

Exclusion criteria

  • Underlying renal or cardiac disease
  • Hypertension
  • Diabetes mellitus
  • Contraceptive use less than 3 months before MOCK cycle, including: IUD (hormonal and copper), hormonal patch, contraceptive pill (combination and mini), hormonal intravaginal ring, contraceptive implant, contraceptive injection.
  • Ovarian stimulation during the previous three months
  • History of recurrent pregnancy loss (defined as 2 or more previous pregnancy losses before 24 weeks gestation).

Treatment and study plan

Blood samples for the analysis of biomarkers.

Diagnostic Test

We will collect several blood samples:

  • One at day 8 of the cycle: measurements of P, E2, Na, K, CL, CO2, Osmolality, PRL, direct renin, PAC, Nt-proBNP, Relaxin-2 and VEGF.
  • One for cycle follow up between day 8 and ovulation: measurement of P, E2, LH
  • One at day 7 after ovulation induction: measurements of P, E2, Na, K, CL, CO2, Osmolality, PRL, direct renin, PAC, Nt-proBNP, Relaxin-2 and VEGF.

Transvaginal ultrasound for follicle and endometrium measurements.

Diagnostic Test

A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.

Mean Arterial Pressure measurement.

Diagnostic Test

The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.

Ovitrelle injection for ovulation induction

Drug

When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.

Primary outcomes

  1. The relationship between progesterone levels and different follicular sizes on day 7 post ovulation induction.

    Time frame: From the start of the menstrual cycle until 7 days after ovulation induction.

    Progesterone levels will be measured 7 days after ovulation induction to relate them to different follicular sizes.

Secondary outcomes

  1. Estradiol evolution throughout the cycle and its relation to luteal progesterone levels.

    Time frame: From the start of a menstrual cycle until 7 days post-ovulation induction.

    We will measure the estradiol on different moments throught the menstural cycle, and see how these levels correspond to later (luteal) progesterone levels.

  2. Indirect factors reflecting cardiovascular and renal adaptation in the luteal phase

    Time frame: From the start of the menstrual cycle until 7 days after ovulation induction.

    We will measure these factors (MAP, progesterone, estradiol, serum sodium, chloride, carbon dioxide and osmolality, prolactin, direct renin, plasma aldosterone, NT-proBNP, relaxin-2 and VEGF) at day 8 of the cycle, as well as 7 days after ovulation-induction. All these factors form a reflection of the body's cardiovascular and renal adaptation, and will be studied to estimate these adaptation at different follicular sizes.

Study contacts

Contact information is provided by the study sponsor or research team.

Caroline Roelens

CONTACT

[email protected]

0032 2 477 9887

Sponsors and collaborators

Lead sponsor

Universitair Ziekenhuis Brussel

Other

Registry information

Acronym: CLEAR

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 15, 2026
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.